The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner

Abstract

Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP317-326, bears anti-malignant activities in vitro and in vivo, such as inhibition of metastatic progression and tumor cell sensitization to cell death induced by various anti-cancer treatments. Recently, we discovered that this RasGAP-derived peptide possesses the ability to directly kill some cancer cells. TAT-RasGAP317-326 can cause cell death in a manner that can be either partially caspase-dependent or fully caspase-independent. Indeed, TAT-RasGAP317-326-induced toxicity was not or only partially prevented when apoptosis was inhibited. Moreover, blocking other forms of cell death, such as necroptosis, parthanatos, pyroptosis and autophagy did not hamper the killing activity of the peptide. The death induced by TAT-RasGAP317-326 can therefore proceed independently from these modes of death. Our finding has potentially interesting clinical relevance because activation of a death pathway that is distinct from apoptosis and necroptosis in tumor cells could lead to the generation of anti-cancer drugs that target pathways not yet considered for cancer treatment.

CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma

“…Gene disruption of the KEAP1 gene was performed using the CRISPR/Cas9 technology as described [39]. The sequences of the sgRNA used for this are shown in Supplementary Figure 1B.…”

Rhein Augments Antiproliferative Effects of Atezolizumab Based on Breast Cancer (4T1) Regression

“…Caspase-8 and caspase-9 and caspase-3 are apoptotic promoters and an apoptotic effector, respectively. After activation by upstream signalling, including caspase-2, caspase-9, and caspase-10, caspase-3 can lyse extracellular substances and cytoskeleton protein or poly ADP-ribose polymerase and other DNA repair-related molecules to induce the apoptosis of tumour cells [20,21]. The level of the ratio of Bax/Bcl-2 mRNA plays an important role in the apoptosis of tumour cells.…”

Genetic, cellular and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

“…TAT-RasGAP 317-326 sensitizes cancer cells to chemo-, radio- and photodynamic therapies ( 16–19 ) and prevents cell migration and invasion ( 20, 21 ). Some cancer cell lines, such as Raji (Burkitt’s lymphoma), SKW6.4 (transformed B-lymphocytes) and HeLa (cervix carcinoma), are directly killed by this peptide ( 22 ). To characterize the mode of entry of TAT-RasGAP 317-326 , Raji, SKW6.4 and HeLa cells were incubated with a FITC-labelled version of the peptide and visualized over time.…”